Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases. Since red blood cells are overproduced in the marrow, this leads to abnormally high numbers of circulating red blood cells within the blood. Consequently, the blood thickens and increases in volume, a condition called hyperviscosity. Thickened blood may not flow through smaller blood vessels properly. A variety of symptoms can occur in individuals with polycythemia vera including nonspecific symptoms such as headaches, fatigue, weakness, dizziness or itchy skin, an enlarged spleen (splenomegaly), a variety of gastrointestinal issues and the risk of blood clot formation, which may prevent blood flow to vital organs such as heart, lungs, kidneys.
Due to the COVID-19 pandemic, the global Polycythemia Vera Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Polycythemia Vera Treatment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Polycythemia Vera Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Antimetabolite accounting for % of the Polycythemia Vera Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Polycythemia Vera Treatment include ANP Technologies, INC., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Galena Biopharma, Inc., Gilead Sciences, Inc, Italfarmaco S.P.A., Karus Therapeutics Limited, Miragen Therapeutics, Inc and Zydus Cadila Incyte Corp., etc. In terms of revenue, the global 3 largest players have a % market share of Polycythemia Vera Treatment in 2021.
This report focuses on Polycythemia Vera Treatment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Polycythemia Vera Treatment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Polycythemia Vera Treatment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Antimetabolite
Inhibitors
Alpha Interferon
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Sales
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
ANP Technologies, INC.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Gilead Sciences, Inc
Italfarmaco S.P.A.
Karus Therapeutics Limited
Miragen Therapeutics, Inc
Zydus Cadila Incyte Corp.
Otsuka America Pharmaceutical, Inc. Pharmaclon
Teva Pharmaceuticals Inc.
Schering-Plough
GNC Vector
Alfarm
Merk and Co. Inc.
Pfizer.
Novartis AG
Bayer AG
Mylan N.V
GlaxosmithKline plc